The senior management of Cantab Biopharmaceuticals Ltd represent a group with significant experience and an impressive track record within the biopharmaceutical industry. Most of the team have worked closely together for over 10 years.
Dr Jim Mills, CEO (Cambridge)
PhD microbial biochemistry; BSc (Hons) biotechnology
16 years experience in the biotechnology industry
After studying a first degree in Biotechnology and a PhD in microbial physiology Jim joined the Process Development group of Cantab Pharmaceuticals in 1997. He was responsible for Upstream Process Development and GMP manufacturing of the companys protein products.
When Cantab merged with Xenova in 2001, Jim continued to work within Process Development at increasing levels of responsibility, becoming Leader for Upstream Process Development by the time Celtic Pharma acquired Xenova in 2005.
Following the acquisition by Celtic Jim took on an increasingly commercial role and was appointed Director of Operations for Xenova Biomanufacturing (Cambridge Biomanufacturing Ltd: CBL) in 2007. As Director of Operations, Jim was responsible for Process and Analytical Development, Manufacturing, Quality, Project Management and Business Development.
With the acquisition of the company by CP2 and it’s refocusing as Cantab Biopharmaceuticals Ltd to concentrate on the development of in-house products within the biosuperiors space, Jim will be driving this strategy, and the company, forward as CEO.
Fiona Hamilton, Leader of Analytical Development (Cambridge)
BSc Hons Biological Chemistry (First Class) and BTec (HNC) Chemistry.
16 years experience in analytical development in the biotechnology industry.
Since 1996, Fiona has been responsible for the development and validation of biochemical assays to ICH guidelines and for performing the assays in the QC release and stability testing of bulk and final biopharmaceutical products for toxicology and Phase I/II clinical trials at Cantab/Xenova. She is experienced in a range of analytical techniques including HPLC, electrophoresis, immunoassays, and protein characterisation assays. She is responsible for applying the principles of GXP to the analytical laboratory and for producing, reviewing and approving associated protocols, SOPs and reports.
Prior to joining Cantab/Xenova, Fiona was responsible for the characterisation of microparticulate formulations in drug delivery and diagnostic research projects at Andaris Ltd, and prior to that spent 2 years at Delta Biotechnology developing novel assays used in the process development and quality control of a recombinant albumin microcapsule product used as an ultrasound contrast agent.
Robert Titmus, Leader of Process Development (Cambridge)
BSc Applied Biology (First Class)
15 years experience in downstream process development in the biotechnology industry.
Rob has operated within the downstream development team at Cantab/Xenova since 1999, taking responsibility for the development of downstream processes for a number of clinical products. He is experienced in a broad range of purification technologies from column and membrane chromatography through to micro and ultra filtration techniques; including virus removal technologies, and also in transferring these through to successful manufacture. In addition to leading the downstream development team, Rob has, since 2001, managed the CMC activities for Xenova/Celtic’s two addiction vaccine programmes.
Rob previously worked within Bio Products Laboratory; the division of the NHS responsible for large scale plasma fractionation; where he developed processes for two monoclonal antibodies and took them through to successful manufacture.